Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer began coverage on shares of Evommune (NYSE:EVMN) in a research note published on Thursday morning, Marketbeat reports. The firm issued an outperform rating and a $42.00 target price on the stock.

EVMN has been the topic of several other research reports. Cantor Fitzgerald began coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “overweight” rating on the stock. William Blair assumed coverage on shares of Evommune in a report on Monday, December 1st. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Evercore ISI began coverage on Evommune in a research report on Monday, December 1st. They issued an “outperform” rating and a $40.00 price target on the stock. Finally, Leerink Partners upgraded Evommune to a “strong-buy” rating in a report on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Evommune currently has a consensus rating of “Buy” and an average price target of $39.17.

Evommune Stock Performance

EVMN stock opened at $18.85 on Thursday. Evommune has a twelve month low of $13.89 and a twelve month high of $24.03. The company has a market capitalization of $594.15 million and a P/E ratio of -2.34. The business’s fifty day moving average price is $18.52.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The company had revenue of $10.00 million during the quarter, compared to analyst estimates of $10.00 million.

Hedge Funds Weigh In On Evommune

A hedge fund recently bought a new stake in Evommune stock. Capricorn Fund Managers Ltd acquired a new position in Evommune, Inc. (NYSE:EVMN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 60,000 shares of the company’s stock, valued at approximately $1,027,000. Capricorn Fund Managers Ltd owned about 0.19% of Evommune as of its most recent SEC filing.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.